Live Breaking News & Updates on Genital Herpes Pipeline|Page 1

25+ active players in the domain working on 25+ pipeline therapies. 
Key Genital Herpes pipeline therapies such as
HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and others are under investigation in different phases of clinical trials for the treatment of Genital Herpes. 
Sanofi, Rational Vaccines, BlueWillow Biologics, Heidelberg, ImmunoTherapeutics, AiCuris, United Biopharma, among several others, are some of the key prominent pharma players working in the domain. 
In
May 2021, X-Vax Technology announced that it is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental vaccine against herpes simplex virus 1 and 2 (HSV-1 and -2).   ....

United States , Bluewillow Biologics , Los Angeles , Heidelberg Immunotherapeutics , Evofem Biosciences , Squarex Pharma , Key Pharmaceutical Companies , Key Genital Herpes Companies , Drug Administration , Delveinsight Due Diligence Services , Key Companies , Route Of Administration , Genital Herpes Pipeline Landscape , Emerging Therapies , Growth Variables , Commercial Assessment , Key Pharmaceutical Companies Active , Genital Herpes , Genital Herpes Pipeline Insight , Genital Herpes Pipeline , Rational Vaccines , United Biopharma , X Vax Technology , Investigational New Drug , Breakthrough Therapy Designation , Genital Herpes Emerging Therapies ,